• OPEN AN ACCOUNT
Indian Indices
Sensex
78,918.90 -1,097.00
( -1.37%)
Global Indices
Nasdaq
47,518.20 -457.55
(-0.95%)
Dow Jones
6,761.35 -90.36
(-1.32%)
Hang Seng
55,600.46 322.40
(0.58%)
Nikkei 225
10,286.75 -127.19
(-1.22%)
Forex
USD-INR
91.74 -0.39
(-0.42%)
EUR-INR
106.47 -0.59
(-0.55%)
GBP-INR
122.42 -0.61
(-0.50%)
JPY-INR
0.58 0.00
(-0.46%)

EQUITY - MARKET SCREENER

3B Blackbio DX Ltd
Industry :  Healthcare
BSE Code
ISIN Demat
Book Value()
532067
INE994E01018
346.1795339
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
21.03
1074.59
EPS(TTM)
Face Value()
Div & Yield %
59.54
10
0.32
 

crysdale industries ltd
Aurobindo Pharma launches Pomalidomide capsules in US market
Mar 04,2026
The product is the generic equivalent of Pomalyst Capsules of BMS Pharmaceuticals Corp. Eugia Pharma Specialities was among the First-to-File (FTF) ANDA applicants. Manufacturing will take place at Eugia Unit-I.

Pomalidomide, a third-generation immunomodulatory drug (IMiD), is used in combination with dexamethasone, and sometimes bortezomib, for relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.

According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The company’s consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

Shares of Aurobindo Pharma shed 0.95% to Rs 1,199.85 on the BSE.